Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEARCA:COMCVE:NVHTSE:ONCNYSEARCA:SCYB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOMDirexion Auspice Broad Commodity Strategy ETF$29.36+0.4%$28.53$27.56▼$31.62$261.30M0.1946,555 shs15,032 shsNVHNovoheartC$0.53+1.9%C$0.53C$0.26▼C$0.72C$99.98MN/A33,593 shs23,066 shsONCOncolytics BiotechC$1.49+1.4%C$1.44C$1.20▼C$4.49C$112.38M1.4977,267 shs62,335 shsSCYBSchwab High Yield Bond ETF$51.13-0.2%$51.65$48.50▼$52.35$140.61M0.3143,089 shs51,948 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOMDirexion Auspice Broad Commodity Strategy ETF+0.41%+0.17%+4.60%+5.50%-5.99%NVHNovoheart0.00%0.00%0.00%0.00%0.00%ONCOncolytics Biotech+1.36%+4.20%+7.97%-9.15%-14.37%SCYBSchwab High Yield Bond ETF-0.23%+0.49%-1.65%-1.81%+5,112,999,900.00%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOMDirexion Auspice Broad Commodity Strategy ETFN/AN/AN/AN/AN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/AN/AN/AN/AONCOncolytics Biotech0.5985 of 5 stars3.50.00.00.01.10.00.0SCYBSchwab High Yield Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOMDirexion Auspice Broad Commodity Strategy ETF0.00N/AN/AN/ANVHNovoheartN/AN/AN/AN/AONCOncolytics Biotech3.00BuyC$6.00302.68% UpsideSCYBSchwab High Yield Bond ETFN/AN/AN/AN/ACurrent Analyst RatingsLatest ONC, SCYB, COM, and NVH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024ONCOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperformC$3.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOMDirexion Auspice Broad Commodity Strategy ETFN/AN/AN/AN/AN/AN/ANVHNovoheartC$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34ONCOncolytics BiotechN/AN/AC$0.35 per share4.22C$0.37 per shareN/ASCYBSchwab High Yield Bond ETFN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOMDirexion Auspice Broad Commodity Strategy ETFN/AN/A0.00∞N/AN/AN/AN/AN/ANVHNovoheartN/A-C$0.04N/A∞N/AN/AN/AN/AN/AONCOncolytics Biotech-C$27.75M-C$0.41N/A∞N/AN/A-102.66%-55.47%5/3/2024 (Estimated)SCYBSchwab High Yield Bond ETFN/AN/A0.00∞N/AN/AN/AN/AN/ALatest ONC, SCYB, COM, and NVH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ONCOncolytics Biotech-C$0.15-C$0.05+C$0.10-C$0.05N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOMDirexion Auspice Broad Commodity Strategy ETF$2.538.62%N/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/AONCOncolytics BiotechN/AN/AN/AN/AN/ASCYBSchwab High Yield Bond ETFN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOMDirexion Auspice Broad Commodity Strategy ETFN/AN/AN/ANVHNovoheart27.626.136.05ONCOncolytics Biotech1.549.018.86SCYBSchwab High Yield Bond ETFN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOMDirexion Auspice Broad Commodity Strategy ETFN/ANVHNovoheartN/AONCOncolytics Biotech6.98%SCYBSchwab High Yield Bond ETFN/AInsider OwnershipCompanyInsider OwnershipCOMDirexion Auspice Broad Commodity Strategy ETFN/ANVHNovoheartN/AONCOncolytics Biotech6.24%SCYBSchwab High Yield Bond ETFN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCOMDirexion Auspice Broad Commodity Strategy ETFN/A8.90 millionN/ANot OptionableNVHNovoheartN/A188.64 millionN/ANot OptionableONCOncolytics Biotech2975.42 millionN/ANot OptionableSCYBSchwab High Yield Bond ETFN/A2.75 millionN/ANot OptionableONC, COM, NVH, and SCYB HeadlinesSourceHeadlineCharles Schwab Results Slump but Beat Expectationswsj.com - April 15 at 8:26 AMSchwab High Yield Bond ETF declares monthly distribution of $0.3201msn.com - April 1 at 4:21 PMSome 'TIPs' For A Better Bond Ladderseekingalpha.com - March 12 at 1:45 AMSCHD and the dividend ETF landscape -- SA analysts weigh inmsn.com - March 5 at 10:05 AMWill Charles Schwab Eyeing Bitcoin ETF Be A Game-Changer For Retail Investors?msn.com - January 29 at 5:22 PMSCHD ETF: Can It Return to Winning Ways in 2024?msn.com - January 4 at 10:27 AMSchwab Asset Management Announces Zero Capital Gains Distributions for Schwab ETFs for 2023tmcnet.com - December 18 at 12:29 PMSCHY: Enjoys A Nice Yield And Cheap Valuation After Underperformingseekingalpha.com - December 10 at 1:00 PMXtrackers USD High Yield Corporate Bond ETF declares monthly distribution of $0.1668msn.com - December 8 at 5:00 PMSchwab’s Unrealized Bond Losses Widened to $19.4 Billion. Why Investors Should Care.msn.com - November 10 at 3:00 PMSchwab (SCHW) Cuts Fees on More Fixed income ETFs to 0.03%finance.yahoo.com - September 26 at 12:33 PMAll of Schwab’s Bond ETFs Now Cost Just Three Basis Pointsfinance.yahoo.com - September 25 at 3:17 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesCanoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetApril 2, 2024 9:15 AMView Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet5 Cheap Dividend Stocks: Which to Buy NowApril 1, 2024 9:55 AMView 5 Cheap Dividend Stocks: Which to Buy NowGE Aerospace is Ready for Liftoff After Strong EarningsApril 24, 2024 9:07 AMView GE Aerospace is Ready for Liftoff After Strong EarningsAll Headlines Company DescriptionsDirexion Auspice Broad Commodity Strategy ETFNYSEARCA:COMThe Direxion Auspice Broad Commodity Strategy ETF (COM) is an exchange-traded fund that is based on the Auspice Broad Commodity index. The fund tracks a broad-market index consisting of 12 commodity futures contracts, weighted by historical volatility, which can toggle to cash based on momentum. The fund will also hold short-term fixed income securities as collateral. COM was launched on Mar 30, 2017 and is managed by Direxion.NovoheartCVE:NVHNovoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.Oncolytics BiotechTSE:ONCOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Schwab High Yield Bond ETFNYSEARCA:SCYBThe Schwab High Yield Bond ETF (SCYB) is an exchange-traded fund that mostly invests in high yield fixed income. The fund tracks an index of USD-denominated high-yield, US corporate bonds, selected and weighted based on market value. SCYB was launched on Jul 11, 2023 and is managed by Charles Schwab. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.